Monte Rosa Therapeutics (GLUE) Competitors $4.90 -0.01 (-0.20%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$4.89 -0.01 (-0.10%) As of 04:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLUE vs. ARDX, DYN, AUPH, SNDX, BGM, ADPT, IOVA, WVE, ETNB, and COLLShould you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Ardelyx (ARDX), Dyne Therapeutics (DYN), Aurinia Pharmaceuticals (AUPH), Syndax Pharmaceuticals (SNDX), Qilian International Holding Group (BGM), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Wave Life Sciences (WVE), 89bio (ETNB), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry. Monte Rosa Therapeutics vs. Ardelyx Dyne Therapeutics Aurinia Pharmaceuticals Syndax Pharmaceuticals Qilian International Holding Group Adaptive Biotechnologies Iovance Biotherapeutics Wave Life Sciences 89bio Collegium Pharmaceutical Monte Rosa Therapeutics (NASDAQ:GLUE) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations. Do analysts rate GLUE or ARDX? Monte Rosa Therapeutics currently has a consensus target price of $15.50, indicating a potential upside of 216.33%. Ardelyx has a consensus target price of $10.61, indicating a potential upside of 93.99%. Given Monte Rosa Therapeutics' higher probable upside, research analysts plainly believe Monte Rosa Therapeutics is more favorable than Ardelyx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Ardelyx 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has better valuation & earnings, GLUE or ARDX? Ardelyx has higher revenue and earnings than Monte Rosa Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$75.62M3.99-$135.35M-$1.02-4.80Ardelyx$333.62M3.91-$39.14M-$0.16-34.19 Is GLUE or ARDX more profitable? Monte Rosa Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -11.73%. Ardelyx's return on equity of -24.87% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa TherapeuticsN/A -62.68% -38.83% Ardelyx -11.73%-24.87%-10.51% Do institutionals & insiders hold more shares of GLUE or ARDX? 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 6.5% of Monte Rosa Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community prefer GLUE or ARDX? Ardelyx received 521 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 67.46% of users gave Ardelyx an outperform vote while only 48.48% of users gave Monte Rosa Therapeutics an outperform vote. CompanyUnderperformOutperformMonte Rosa TherapeuticsOutperform Votes1648.48% Underperform Votes1751.52% ArdelyxOutperform Votes53767.46% Underperform Votes25932.54% Does the media prefer GLUE or ARDX? In the previous week, Ardelyx had 8 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 12 mentions for Ardelyx and 4 mentions for Monte Rosa Therapeutics. Ardelyx's average media sentiment score of 1.06 beat Monte Rosa Therapeutics' score of 0.82 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, GLUE or ARDX? Monte Rosa Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. SummaryArdelyx beats Monte Rosa Therapeutics on 12 of the 19 factors compared between the two stocks. Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLUE vs. The Competition Export to ExcelMetricMonte Rosa TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$301.40M$2.95B$5.53B$7.93BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-2.6830.0722.5918.54Price / Sales3.99494.82401.35103.29Price / CashN/A168.6838.1834.62Price / Book1.373.176.774.25Net Income-$135.35M-$72.35M$3.22B$248.18M7 Day Performance-3.16%2.14%1.39%1.03%1 Month Performance11.11%5.67%2.78%2.70%1 Year Performance-12.50%-23.57%15.85%4.05% Monte Rosa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLUEMonte Rosa Therapeutics1.9753 of 5 stars$4.90-0.2%$15.50+216.3%-17.5%$301.40M$75.62M-2.6890Upcoming EarningsShort Interest ↑News CoverageARDXArdelyx4.5654 of 5 stars$4.56-5.4%$10.61+132.7%-17.2%$1.09B$333.62M-28.5090Earnings ReportNews CoveragePositive NewsDYNDyne Therapeutics3.3267 of 5 stars$9.33+14.2%$47.46+408.7%-53.6%$1.06BN/A-2.62100Short Interest ↑High Trading VolumeAUPHAurinia Pharmaceuticals2.6535 of 5 stars$7.66-1.2%$11.50+50.1%+57.7%$1.05B$235.13M-51.06300SNDXSyndax Pharmaceuticals3.6451 of 5 stars$11.93+3.4%$36.20+203.4%-37.1%$1.03B$23.68M-3.29110Upcoming EarningsPositive NewsBGMQilian International Holding GroupN/A$10.52-4.4%N/AN/A$1.02B$25.10M0.00298ADPTAdaptive Biotechnologies4.1405 of 5 stars$6.83-6.8%$9.40+37.6%+163.8%$1.01B$178.96M-6.27790Earnings ReportNews CoveragePositive NewsIOVAIovance Biotherapeutics4.5717 of 5 stars$3.08+0.7%$18.22+491.6%-73.4%$1.01B$164.07M-2.07500Upcoming EarningsPositive NewsWVEWave Life Sciences4.313 of 5 stars$6.12+3.4%$22.18+262.4%+40.0%$939.33M$108.30M-5.51240Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageETNB89bio2.9742 of 5 stars$6.27+3.5%$27.56+339.5%-7.1%$915.32MN/A-2.1540Earnings ReportUpcoming EarningsAnalyst UpgradeNews CoveragePositive NewsCOLLCollegium Pharmaceutical4.0345 of 5 stars$26.91-0.4%$43.60+62.0%-28.4%$864.67M$631.45M11.60210Upcoming EarningsPositive News Related Companies and Tools Related Companies ARDX Alternatives DYN Alternatives AUPH Alternatives SNDX Alternatives BGM Alternatives ADPT Alternatives IOVA Alternatives WVE Alternatives ETNB Alternatives COLL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLUE) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLUE Stock Free GLUE Stock Alerts